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Intrauterine growth restriction (IUGR) is an important perinatal syndrome that poses several serious short- and long-term eﬀects.
We studied cytokine production by maternal peripheral blood lymphocytes stimulated by trophoblast antigens. 36 women with
a diagnosis of IUGR and 22 healthy women with normal fetal growth were inducted. Peripheral blood mononuclear cells were
stimulated with trophoblast antigens and levels of the proinﬂammatory cytokines IL-6, IL-8, IL-12, IL-23, IFNγ, and TNFα and
the anti-inﬂammatory cytokines IL-4, IL-10, and IL-13 were measured in culture supernatants by ELISA. IL-8 was produced at
higher levels byblood cells oftheIUGR group than normal pregnant women,while IL-13was produced at lower levels. IL-8,IFNγ,
and TNFα were higher in IUGR with placental insuﬃciency than in normal pregnancy. IL-12 levels were higher and IL-10 levels
were lower in IUGR with placental insuﬃciency than in IUGR without placental insuﬃciency. We suggest that a stronger pro-
inﬂammatory bias exists in IUGR as compared to normal pregnancy and in IUGR with placental insuﬃciency when compared to
IUGRwithout placental insuﬃciency. Several ratiosof proinﬂammatoryto anti-inﬂammatorycytokines alsosupporttheexistence
of an inﬂammatory bias in IUGR.
1.Introduction
Intrauterine growth restriction (IUGR) is one of the most
important perinatal syndromes and is a worldwide problem.
IUGR, deﬁned as fetal growth less than the 10th percentile
for gestational age [1], puts the fetus and neonate at higher
risk for perinatal mortality and morbidity [2] and the
child at a permanent risk for a range of disorders that
include cardiovascular and renal disease, and hypertension
[3].Aﬀectedbabieshavea30–50%likelihoodofintrapartum
hypoxic distress and a 50% risk of neonatal complications
that include hypoglycemia, meconium aspiration pneumo-
nia, and long-term growth impairment [4].
Intrauterine growth restriction is segregated into two
types, IUGR with placental insuﬃciency (or asymmetric
IUGR) and IUGR without placental insuﬃciency (or sym-
metric IUGR). IUGR without placental insuﬃciency is
believed to be an early embryonic event, is constitutional,
and is generally attributable to genetic and chromosomal
abnormalities, fetal malformation, and infections. Infants
of such pregnancies have both length and weight below
normal for gestational age; placentas are usually small by
weight, but have no other pathologies [5]. On the other
hand,IUGRwithplacentalinsuﬃciency(asymmetricIUGR)
occurs later in gestation and usually involves a more severe
growth restriction of the abdomen than of the head [6]; such
pregnancies usually have signiﬁcant placental pathological
ﬁndings. IUGR with placental insuﬃciency is believed to be
due to maternal diseases that bring about a reduction of
uteroplacental blood ﬂow [6].
Despite the delineation of several of the causes and risk
factors of IUGR (5–20% due to chromosomal abnormalities,
5–20% due to maternal and fetal vascular disorders and
infections [6]), a deﬁnite cause of IUGR is not identiﬁed2 Clinical and Developmental Immunology
in 40–50% of all cases [7]. Logically an insuﬃcient blood
ﬂow to the placenta is the ﬁrst abnormality to suspect and
indeed a signiﬁcant proportion of IUGR cases is associated
withplacentalﬁndings,pointingtoproblemsinfetoplacental
circulation [8]. Indeed, the lack of suﬃcient transport of
nutrients and oxygen to the fetus is commonly recognized
as leading to IUGR [8], but in a number of cases restricted
growth cannot be explained by placental insuﬃciency alone
[8]. In addition to the genetic and constitutional disorders
mentioned above, it is appropriate to look at possible
immunologiceventsthatmayleadtoIUGRwithandwithout
placental suﬃciency.
Maternal immunologic factors such as cytokines, natural
killer (NK) cells, activated macrophages, and lymphocytes
have been shown to be associated with several pregnancy
complications such as recurrent spontaneous miscarriage,
preeclampsia, and preterm delivery. Cytokines have been
shown to play vital roles in normal pregnancy both in the
maintenance of placental growth and in the modulation
of maternal immune reactivity to prevent rejection of the
conceptus [9, 10]. The maternal immunologic state that
is most conducive to successful pregnancy is maintained
by local secretion of T helper-2 (Th2) cytokines and some
types of pregnancy complications seem to be associated
with a predominance of T helper-1 (Th1) reactivity in
the mother; this appears to be the case for recurrent
spontaneous miscarriage [11–13], preterm delivery [14, 15],
and preeclampsia [16, 17].
Th1 and Th2 cells are two of the major subsets of
CD4+ T-helper cells; they have diﬀerent cytokine produc-
tion proﬁles and accordingly diﬀerent roles in immune
responses. Th1 cells secrete the proinﬂammatory cytokines
IL-2, IFNγ,T N F α,a n dT N F β which activate macrophages
and cell-mediated reactions relevant to cytotoxic reactions
and delayed-type hypersensitivity [18, 19]. Th2 cells secrete
IL-4, IL-5, IL-10, and IL-13 which induce vigorous humoral
immunity [18, 19]. Th1 cytokines tend to be inﬂammatory
cytokines, while some of the Th2 cytokines tend to have anti-
inﬂammatory properties.
While there are numerous studies on cytokine proﬁles in
pregnancy complications like recurrent miscarriage, preterm
delivery, and pre-eclampsia [9–17, 20–22], immunological
studies in IUGR are relatively small in number. There
are few reports on cytokine levels in IUGR. Some studies
have estimated cytokines in serum and amniotic ﬂuid, but
none have yet focused on cytokine production by maternal
lymphocytes. We stimulated maternal peripheral blood
mononuclear cells from IUGR pregnancies and normal
pregnancieswithatrophoblastantigenextractandexamined
the resulting cytokine production pattern to explore possible
relationships between cytokines and IUGR with placental
insuﬃciency and without placental insuﬃciency.
2.MaterialsandMethods
2.1. Subjects. This study has the approval of the Ethics
Committee of the Faculty of Medicine, Kuwait Univer-
sity; healthy pregnant women (controls) and subjects
with IUGR were inducted into this study after informed
consent was obtained from them. Subjects were enrolled
at two high-risk pregnancy clinics at Kuwait Maternity
Hospital, a tertiary center. Consecutive cases with IUGR
were enrolled into the study. All subjects gave informed
consent. This prospective study included 36 women with
a diagnosis of IUGR and 22 control healthy women with
normal fetal growth attending the antenatal clinic at Kuwait
Maternity Hospital (Table 1). Power analysis, conducted
using the G∗Power statistics program (http://www.psycho
.uni-duesseldorf.de/abteilungen/aap/gpower3)[ 23]b a s e d
on median levels of cytokines measured in our previous
studies on cytokines in pregnancy [13, 17, 21], indicated
that these sample numbers are adequate to demonstrate
diﬀerences at the 95% conﬁdence interval.
E a r l yu l t r a s o u n ds c a nw a sc o n d u c t e do na l ls u b j e c t s
to conﬁrm gestational age; inclusion criteria for the IUGR
group were fetuses with less than 10th centile abdominal
circumference. The 36 women in the IUGR group were
further subdivided into 19 IUGR pregnancies with placental
insuﬃciency and 17 IUGR pregnancies without placental
insuﬃciency by assessment of fetal anatomy and biometry,
amniotic ﬂuid dynamics, uterine, umbilical, and fetal middle
cerebralarteryDoppler.Bloodvelocitywaveformsfromboth
uterine arteries, the umbilical artery and the fetal middle
cerebral artery, were measured using duplex pulsed-wave
Doppler Ultrasound Scanner (ALOKA SSD-650) with 3.5-
MHZ convex transducer. Pulsatility Index was calculated as
(Systolic/Diastolic)/Systolic as described in [24]. Placental
insuﬃciency was diagnosed if pulsatility index in the umbil-
ical artery was raised, with either absent or reversed end
diastolic ﬂow. Doppler measurements were performed by a
single investigator.
The control group consisted of 22 women who had
a history of at least two previous successful pregnancies
with no previous spontaneous miscarriage, pre-eclampsia,
preterm labor or IUGR.
2.2. Isolation of Peripheral Blood Mononuclear Cells. Five mL
of venous blood samples were taken from all subjects within
24 hours of delivery. Peripheral blood mononuclear cells
(PBMC) were separated from the blood samples by Ficoll-
Hypaque (GE Healthcare, Uppsala, Sweden) density gradi-
ent centrifugation, suspended in RPMI medium (GIBCO,
Auckland, New Zealand) containing 10% fetal calf serum,
aliquoted into 96-well tissue culture plates at a density of
105 cells per well and then challenged with the trophoblast
antigen extract as described below.
2.3. Trophoblast Antigen Stimulation of PBMC. Trophoblast
antigen extracts were prepared as described previously [20–
22] from the human gestational choriocarcinoma cell line
JEG-3 (American Type Culture Collection, Md, USA), which
is of trophoblastic origin. JEG cells were cultured in RPMI-
1640 medium until 80% conﬂuence is reached, harvested
without trypsinization using a rubber cell scraper, washed
three times in medium and then disrupted in a Dounce
homogenizer (∼100 strokes). The suspension was then cen-
trifuged at 3000rpm for 10 minutes, the supernatant ﬁlteredClinical and Developmental Immunology 3
Table 1: Demographic data on subjects in this study.
Control
N = 22
IUGR
N = 36 P value
IUGR with placental
Insuﬃciency
N = 19
IUGR without placental
Insuﬃciency
N = 17
P value
Maternal age 32.4 ± 4.2 35.1 ± 3.7 NS 34.6 ± 3.3 36.1 ± 4.3 NS
Mode of delivery
C.S. 6 15 — 96 —
S.V.D 16 21 10 11
Outcome
Preterm 2 8 — 62 —
Term 20 28 13 15
Birthweight (Kg) 3.6 ± 1.2 2.3 ± 0.7 <0.001 2.0 ± 0.9 1.9 ± 0.6 NS
NS: Nonsigniﬁcant; C.S.: Caesarian section; S.V.D.: Single vaginal delivery.
through a 0.20μMﬁ l t e r ,a l i q u o t e da n ds t o r e da t−20◦C until
use. This material was used to stimulate maternal peripheral
blood cells. Maternal PBMCs were stimulated at a density of
105 cells per well with JEG antigen. Initial standardization
experiments in our laboratory (data not shown) showed
that the optimal concentration for cell proliferation upon
stimulation was 30μg/mL. PBMCs were cultured for 4 days
after antigen stimulation, after which supernatants were
collected for cytokine estimation.
2.4. Determination of Cytokine Levels by ELISA. Levels of the
proinﬂammatory cytokines IL-6, IL-8, IL-12, IL-23, IFNγ,
and TNFα and the anti-inﬂammatory cytokines IL-4, IL-
10 and IL-13 in trophoblast antigen-stimulated cell culture
supernatants were measured by ELISA. Kits for estimating
IL-4, IL-8, IL-10, IL-12, IFNγ and TNFα were obtained
from Beckman-Coulter (Marseilles, France), IL-13 kits from
R & D Systems (Minneapolis, Minn, USA) and IL-23 kits
from Bender Medsystems (Vienna, Austria). Sensitivities of
the kits and the reproducibilities within and between assays
are provided in the appendix below. The manufacturer’s
protocols were followed for these assays which are based
on the antibody sandwich principle. Samples were tested
in triplicate and absorbance values read using an ELISA
Reader. Accurate sample concentrations of cytokines were
determined by comparing their respective absorbancies with
those obtained for the reference standards plotted on a
standard curve.
2.5. Statistical Analyses. The standard Mann-Whitney-U test
wasusedfornonparametriccomparisonsofmediancytokine
levels, as the data were not normally distributed. Diﬀerences
were considered signiﬁcant if the P value ≤0.05.
3. Results
We stimulated maternal PBMC with the trophoblast antigen
extract and then measured the levels of the proinﬂammatory
cytokines IL-6, IL-8, IL-12, IL-23, IFNγ and TNFα and the
anti-inﬂammatory cytokines IL-4, IL-10 and IL-13. Median
levels of cytokines were compared for statistical signiﬁcance.
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Figure 1: Mean levels of the anti-inﬂammatory cytokines IL-4, IL-
10, and IL-13 produced by PBMC from normal pregnancy (N),
a l lI U G Rs u b j e c t s( I), IUGR with placental insuﬃciency (W), and
IUGR without placental insuﬃciency (WO).4 Clinical and Developmental Immunology
We also calculated the means of ratios of proinﬂammatory
toanti-inﬂammatorycytokines(e.g.,IFNγ/IL-4,IL-8/IL-10).
This was done to determine whether bias or dominance of
pro- or anti-inﬂammatory cytokines exists in the stimulated
cultures. The following groups were compared statistically:
IUGR versus normal pregnancy, IUGR with placental insuf-
ﬁciency versus normal pregnancy, IUGR without placental
insuﬃciency versus normal pregnancy and ﬁnally IUGR
with placental insuﬃciency versus IUGR without placental
insuﬃciency.
3.1. Comparison of Cytokine Proﬁles in IUGR versus Nor-
mal Pregnancy. We found signiﬁcantly higher levels of the
proinﬂammatory cytokine IL-8 (mean ± SEM = 1780pg/mL
± 44) in IUGR (i.e., all IUGR pregnancies) as compared
to normal pregnancy (mean ± SEM = 1049pg/mL ± 45)
(P < 0.0001) (Figure 2). We also found signiﬁcantly lower
levels of the anti-inﬂammatory cytokine IL-13 in IUGR
(8.9pg/mL ± 1.6) versus normal pregnancy (15.3pg/mL ±
2.6) (P < 0.02) (Figure 1). The IL-8/IL-13 ratio is also higher
in IUGR as compared to normal pregnancy (P < 0.0005).
Other cytokine ratios which are signiﬁcantly higher in IUGR
than in normal pregnancy are IL-12/IL-13 (P < 0.02), IL-
6/IL-13 (P < 0.01) and TNFα/IL-13 (P < 0.02) (Table 2).
Othercytokineratioswerenotsigniﬁcantlydiﬀerentbetween
IUGR and normal pregnancy. Based on the higher levels of
IL-8, the lower levels of IL-13 and the higher mean cytokine
ratios mentioned above, we suggest that a proinﬂammatory
cytokine pattern exists among PBMC from IUGR subjects.
However, we found higher levels of the proinﬂammatory
cytokine IL-23 in normal pregnancy (479pg/mL ± 15) than
in IUGR (356pg/mL ± 13) (P < 0.0001). The IL-23/IL-4
(P < 0.003)andIL-23/IL-10(P <0.005)ratiosarealsohigher
in IUGR versus normal pregnancy.
3.2. Comparison of Cytokine Proﬁles in IUGR with Placental
Insuﬃciency versus Normal Pregnancy. The levels of the
proinﬂammatory cytokines IL-8 (1803pg/mL ± 89, P <
0.001), IFNγ (126pg/mL ± 33, P < 0.02), and TNFα
(340pg/mL ± 46, P < 0.04) are signiﬁcantly higher in
IUGR with placental insuﬃciency as compared to normal
pregnancy (1049pg/mL ± 45, 18pg/mL ± 6, 70pg/mL ± 21,
resp.). The IL-12/IL-13 and IL-12/IL-10 ratios are signif-
icantly higher in IUGR with placental insuﬃciency when
compared to normal pregnancy (P < 0.04 in both cases)
(Table 2). The higher ratios and the higher levels of IL-8,
IFNγ,a n dT N F α are suggestive of a higher proinﬂammatory
bias in IUGR with placental insuﬃciency than in normal
pregnancy. None of the other cytokines, except for IL-23
(Figure 3),andnoneoftheotherratios,exceptforIL-23/IL-4
were signiﬁcantly diﬀerent; IL-23 levels were signiﬁcantly
higher in normal pregnancy (479pg/mL ± 15) versus IUGR
with placental insuﬃciency (350pg/mL ± 24) (P < 0.0001)
andtheIL-23/IL-4ratiowasalsohigherinnormalpregnancy
(P < 0.01).
3.3. Comparison of Cytokine Proﬁles in IUGR without Pla-
cental Insuﬃciency versus Normal Pregnancy. The proin-
ﬂammatory cytokine IL-8 is produced at higher levels
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Figure 2: Mean levels of the proinﬂammatory cytokines IL-6, IL-
8, and IL-12 produced by PBMC from normal pregnancy (N), all
IUGR subjects (I), IUGR with placental insuﬃciency (W), and
IUGR without placental insuﬃciency (WO).
by PBMC from IUGR without placental insuﬃciency
(1793pg/mL ± 33) than by PBMC from normal pregnant
controls(1049pg/mL ±45)(P <0.0001).Ontheotherhand,
the anti-inﬂammatory cytokine IL-13 is produced at lower
levels by PBMC from IUGR without placental insuﬃciency
(5.8pg/mL ± 1) than by PBMC from normal pregnant
controls (15.3pg/mL ± 2.6) (P < 0.002) (Figures 1 and 2).
Two of the ratios, IL-6/IL-13 (P < 0.006) and IL-8/IL-13 (P <
0.001), were signiﬁcantly higher in IUGR without placental
insuﬃciency compared to normal pregnancy. However, the
IFNγ/IL-10 ratio was actually higher in normal pregnancy
than in IUGR without placental insuﬃciency (P < 0.03)
(Table 2). The higher IL-8 levels and the lower IL-13Clinical and Developmental Immunology 5
Table 2: Means of ratios of proinﬂammatory to anti-inﬂammatory cytokines. All possible combinations of pro- and anti-inﬂammatory
cytokines were compared, but only the ones which are signiﬁcantly diﬀerent are presented in this table. I > N indicates that the ratio is
higher in IUGR than in normal pregnancy, WO > N indicates that the ratio in IUGR without placental insuﬃciency subgroup is higher than
in normal pregnancy group, and so on.
Cytokine ratio
Normal pregnancy
control
(N)
Total IUGR
(I)
IUGR with placental
insuﬃciency
(W)
IUGR without placental
insuﬃciency
(WO)
Signiﬁcant
diﬀerences
IL-6/IL-13 3265 18134 7142 22189 I > N
WO > N
IL-8/IL-10 6 7 9 4 W > WO
IL-8/IL-13 197 1169 526 1285 I > N
WO > N
IL-12/IL-4 14 17 26 10 W > WO
IL-12/IL-10 0.04 0.08 0.13 0.04 W > N
W > WO
IL-12/IL-13 1.4 6 4 8 I > N
W > N
IFNγ/IL-10 0.14 0.23 0.44 0.09 N > WO
TNFα/IL-13 11 210 91 101 I > N
IL-23/IL-4 357 248 210 273
N > I
C > W
N > WO
IL-23/IL-10 23 1.4 1.7 1.2 N > I
N > WO
IL-23/IL-13 58 230 99 238 N > WO
levels suggest that there appears to be a shift towards a
proinﬂammatorybias.Asinthetwocomparisonsmentioned
above, IL-23 levels were signiﬁcantly higher in normal
pregnancy(479pg/mL ±15)thaninIUGRwithoutplacental
insuﬃciency (361pg/mL ± 13) (P < 0.0001) as were the
ratios of IL-23/IL-4, IL-23/IL-10, and IL-23/IL-13 (P < 0.03,
P < 0.01, and P < 0.03, resp.).
3.4. Comparison of Cytokine Proﬁles in IUGR with and
without Placental Insuﬃciency. The proinﬂammatory Th1-
inducing cytokine IL-12 is produced at higher levels in
IUGR with placental insuﬃciency (29pg/mL ± 3.3) than
in IUGR without placental insuﬃciency (12pg/mL ± 2.1)
(P < 0.01). On the contrary, the anti-inﬂammatory Th2
cytokine IL-10 is produced at lower levels in IUGR with
placental insuﬃciency (240pg/mL ± 29) as compared to
IUGR without placental insuﬃciency (421pg/mL ± 55) (P <
0.01). None of the other cytokines are signiﬁcantly diﬀerent.
Three of the proinﬂammatory:anti-inﬂammatory cytokine
ratios are higher in IUGR with placental insuﬃciency;
these are IL-12/IL-10 (P < 0.005), IL-12/IL-4 (P < 0.02),
and IL-8/IL-10 (P < 0.01). We infer from this data that
a stronger proinﬂammatory cytokine bias exists in IUGR
with placental insuﬃciency as compared to IUGR without
placental insuﬃciency.
4. Discussion
This study was undertaken with the expectation that studies
of this sort may lead to the identiﬁcation of immunologic
etiologies of fetal growth restriction or to immune-mediated
pathophysiologic mechanisms that could lead to fetal growth
restriction even if the initial etiology is nonimmunologic.
While previous studies have reported the estimation of
cytokine levels in the serum of women with IUGR, this
is the ﬁrst to present data on cytokine production proﬁles
of maternal lymphocytes after stimulation with trophoblast
antigens. T lymphocytes can be activated with mitogen, anti-
CD3, and with antigens; in this study we chose to stim-
ulate maternal T lymphocytes in PBMC with trophoblast
antigens. The trophoblast cell line, JEG-3, used to prepare
a trophoblast antigen extract has characteristics similar to
early normal human trophoblast cells, including invasive
characteristics, endocrine, and antigenic features. Previous
studies using antigen extracts from this cell line [20–22]
demonstrated higher Th1-type reactivity and lower Th2-
type to trophoblast antigens in women with unexplained
recurrent miscarriage as compared to women with a history
of normal pregnancy.
We found interesting diﬀerences in the levels of some
pro- and anti-inﬂammatory cytokines between IUGR and
normal pregnancy and between IUGR with and without
placental insuﬃciency.
The proinﬂammatory chemotactic cytokine IL-8 is con-
sistently produced at signiﬁcantly higher levels in IUGR
subjects as a group when compared to normal pregnancy,
and also in IUGR with placental insuﬃciency and IUGR
without placental insuﬃciency as compared to normal
pregnancy.IL-8isinducedbyavarietyofstimulithatinclude
lipopolysaccharide, live bacteria, and other proinﬂammatory6 Clinical and Developmental Immunology
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Figure 3: Mean levels of the proinﬂammatory cytokines IL-23,
IFNγ, and TNFα produced by PBMC from normal pregnancy (N),
a l lI U G Rs u b j e c t s( I), IUGR with placental insuﬃciency (W), and
IUGR without placental insuﬃciency (WO).
cytokines such as TNF and IL-1 [25] and it, in turn, induces
chemotaxis of inﬂammatory cells. It is the principal recruiter
of neutrophils, the signature cell of acute inﬂammatory
responses. In addition to recruiting cells to the site of
inﬂammation, IL-8 also retains cells once they have arrived
and stimulates neutrophils to a higher state of activation
[25]. IL-8 is relatively unique in that it is produced early
in the inﬂammatory response but persists for a prolonged
period of time, unlike other proinﬂammatory cytokines that
are usually made and cleared in a matter of hours in vivo.
IL-8 is thus a key inducer and sustainer of local tissue
inﬂammation [26].
Increased maternal and umbilical cord serum levels of
IL-8 were recently shown to be higher in pre-eclampsia
complicated by IUGR than in pre-eclampsia with normal
f e t a lg r o w t h[ 27, 28]. However, this was not reﬂected in a
study by Johnson et al. [29] who found no diﬀerences in
the levels of IL-8 in IUGR versus normal pregnancy. Hahn-
Zoricetal.[30]foundhigherplacentallevelsofIL-8inIUGR
compared with appropriately developed neonates. It has
been suggested that local action of cytokines like IL-8 may
be responsible for the increased inﬁltration of macrophages
that are seen in IUGR, and activated macrophages could
contribute to placental dysfunction [31].
In addition to the higher production of IL-8 by PBMC
from women with IUGR, the proinﬂammatory cytokines
IFNγ and TNFα are also produced at higher levels in IUGR
with placental insuﬃciency versus normal pregnancy. IFNγ
and TNFα are the prime culprits in the development of
chronic inﬂammation [32] and both of them are cytotoxic
cytokines that induce apoptosis of target cells. IFNγ, a classi-
calTh1cytokine,isacrucialinducerofTh1developmentand
aﬀects the activation and function of a variety of cells that
include T cells, B cells, macrophages, and NK cells. TNFα is
one of the most prominent inﬂammatory mediators and ini-
tiates inﬂammatory reactions of the innate immune system,
including the induction of cytokine production, activation,
and expression of adhesion molecules and thrombosis [33].
Along with IL-1 and IL-6, TNFα induces many of the
localized changes seen in acute inﬂammatory reactions such
as increased vascular permeability, induction of chemokine
production, and the expression of adhesion molecules on
vascular endothelia.
Neta et al. [34] reported that lower levels of IFNγ
were associated with a reduced risk of small-for-gestational
age babies and suggest that lower levels of IFNγ could
indicate impairment of trophoblast function leading the
authors to support a protective role for IFNγ. This is in
contrast to our observation that IFNγ is produced at higher
concentrations by PBMC from women with IUGR with
placental insuﬃciency.
While there appear to be diﬀerences in observations on
IFNγ in IUGR, evidence for an association between TNFα
and IUGR seems to be compelling. Increased levels of TNFα
have been reported in the serum of pregnancies complicated
with IUGR [35]. Amarilyo et al. [36] showed higher levels
of TNFα in the cord blood of IUGR infants and suggest that
a state of inﬂammation exists in such infants. TNFα levels
in maternal and umbilical cord serum are reported to be
higher in pre-eclampsia complicated by IUGR than in pre-
eclampsia with normal fetal growth [25]. Holcberg et al. [37]
found that increased TNF secretion in placentas of IUGR
fetuses is related to enhanced vasoconstriction of the fetal
placental vascular bed, and Rogerson et al. [38]r e p o r t e d
that placental TNFα levels are increased in low birth weight
infants associated with malaria.
Overproduction of TNFα and other proinﬂammatory
cytokines has been proposed to be important in the develop-
ment of fetal growth restriction in response to hypoxia [39],
possibly by decreasing amino acid uptake by the fetus [40].Clinical and Developmental Immunology 7
TNFα has other eﬀects on the placenta that may be relevant;
it inhibits the growth of the trophoblast [41], interferes with
placental development and invasion of the spiral arteries, is
directly toxic to endothelium, and may damage the decidual
vasculature [42]. TNF interferes with the anticoagulant
system and may induce placental thrombosis [43]. Holcberg
et al. [37] found that increased TNF secretion in placentas of
IUGR fetuses is related to enhanced vasoconstriction of the
fetal placental vascular bed.
Perhaps the most likely mechanism by which TNFα may
contribute to IUGR is by causing apoptosis of trophoblast
cells. Trophoblast cells of pregnancies with IUGR are more
sensitive to apoptosis in response to cytokines and hypoxia
when compared to trophoblast cells from normal pregnan-
cies, and it is speculated that this dysregulated apoptosis
may lead to the placental dysfunction seen in IUGR [44].
The apoptotic eﬀect of TNFα is well known; it has been
shown to kill trophoblast cells [45], and it is likely that the
increased apoptosis in IUGR is due in part to cytokines like
TNFα[46].Infact,IUGRhasbeenshowntobecharacterized
by enhanced trophoblast apoptosis, and this has been
suggestedtoleadtoabnormalplacentation,inadequatespiral
artery remodelling, and uteroplacental vascular insuﬃciency
[47].
If proinﬂammatory cytokines, such as IL-8 and TNFα,
pose the risk of adverse outcomes of pregnancy, presumably
these may have to be countered by anti-inﬂammatory
cytokines. Indeed, the levels of the anti-inﬂammatory
cytokine IL-13 are higher in normal pregnancy as compared
to the IUGR group and to IUGR without placental insuﬃ-
ciency; we also observed a trend towards lower IL-13 levels
in IUGR with placental insuﬃciency (P < 0.059). IL-13 is
a Th2 cytokine with anti-inﬂammatory properties. IL-13
inhibits the production of the inﬂammatory cytokines IL-6,
IL-12, TNFα, and IL-8, prevents pathological inﬂammation
at mucosal surfaces, and inhibits cytotoxicity [48]. The
enhanced levels of IL-13 in normal pregnancy versus IUGR
may reﬂect a stronger Th2 bias or an anti-inﬂammatory
cytokine bias in normal pregnancy. Further, Dealtry et
al. [49] demonstrated the expression of IL-13 by human
trophoblast cells and suggest that IL-13 may play important
rolesinmaternal-fetaldialoguethataidsintheestablishment
and maintenance of the placenta. Thus, the decreased levels
of IL-13 production in IUGR observed in this study may be
pertinent.
In addition to the proinﬂammatory bias in IUGR
suggested by elevated levels of IL-8 and decreased levels of
IL-13, a comparison of pro- to anti-inﬂammatory cytokines
is also interesting. Ratios of IL-6/IL-13, IL-8/IL-13, IL-12/
IL-13, and TNFα/IL-13 are all signiﬁcantly higher in the
IUGR group compared to normal pregnancy (Table 2). The
IL-12/IL-13 and IL-12/IL-10 ratios are higher in IUGR
with placental insuﬃciency, also suggestive of a stronger
inﬂammatory skew in IUGR with placental insuﬃciency.
Pregnancy has been suggested to bring about a mild state
of inﬂammation [50] ,a n dL ia n dH u a n g[ 31] speculate that
exaggeratedorexcessiveinﬂammationcouldresultinadverse
outcomes such as IUGR via a vicious cycle of coagulation,
thrombosis, and inﬂammation. Thus, mutually enhancing
cascades of coagulation and inﬂammation may be part of the
etiopathogenesis of IUGR.
One of the objectives of this study was to compare IUGR
with and without placental insuﬃciency. IUGR without
placental insuﬃciency is, generally, due to constitutional
causes in the absence of obvious placental pathologies, while
IUGR with placental insuﬃciency manifests with signiﬁcant
placentalpathology and decreasedmaternal-fetalblood ﬂow.
ThisledustospeculatethatIUGRpregnancieswithplacental
insuﬃciency may have a predominant proinﬂammatory
cytokine bias. Our data suggests that this might indeed
be the case. IL-12 levels are signiﬁcantly higher in IUGR
with placental insuﬃciency (Figure 2), while IL-10 levels are
signiﬁcantly lower (Figure 1). Three of the ratios are also
higher in IUGR without placental insuﬃciency: IL-12/IL-
10, IL-12/IL-4, and IL-8/IL-10. None of the other cytokine
ratiosweresigniﬁcantlydiﬀerentbetweenthetwosubgroups.
While this study should have ideally included cases of non-
IUGR with placental insuﬃciency, our data suggests that
there is a stronger tilt towards proinﬂammatory cytokines
in IUGR with placental insuﬃciency than in IUGR without
placental insuﬃciency.
The lower-level of IL-10 in IUGR with placental insuﬃ-
ciency is interesting as it is perhaps the most important anti-
inﬂammatory cytokine found within the human immune
response. It inhibits Th1 cytokine release, NF-κB signaling,
expression of HLA class II molecules, macrophage, and
dendritic cell function [51]. As IL-10 has profound anti-
inﬂammatory properties, the decreased levels of IL-10 in
IUGR with placental insuﬃciency, may be indicative of a
lower proinﬂammatory bias in this subgroup versus IUGR
without placental insuﬃciency subgroup. Previous studies
have shown decreased levels of IL-10 in the placentas of
IUGR pregnancies and this has been suggested to be relevant
to the pathogenesis of IUGR [30]. Given its ability to inhibit
the synthesis of proinﬂammatory cytokines and macrophage
activity and its role in reducing apoptosis [52], IL-10 may, in
part, be responsible for the maintenance of a balance against
a proinﬂammatory bias in normal pregnancy.
IL-23 levels in this study present an interesting conun-
drum; we found signiﬁcantly higher-levels of IL-23 in
normal pregnancy as compared to the three IUGR groups in
trophoblast antigen-stimulated cultures. IL-23 is known to
havemanysimilaritiestoIL-12.AlongwithIL-12,IL-23plays
an important role in bridging innate and acquired immune
responsesandcausesmultiorganinﬂammationwithelevated
expression of inﬂammatory cytokines like TNFα and IL-1
[53]. It is not immediately apparent how lower levels of
IL-23 are related to the pathogenesis of IUGR, but there
are a few interesting leads. IL-23 is not required for Th1
responses and it appears to act not via the Th1 pathway but
along the IL-23/IL-17 pathway of inﬂammatory responses;
in fact the addition of IL-23 to murine T-cell cultures
pushes Th development away from Th1/IFNγ diﬀerentiation
[53]. Remarkably enough, IL-23 has been proposed to
actually oﬀer protection against the deleterious eﬀects of
TNF in implantation, explaining embryo survival in a TNF-
rich environment [54]. Also, Vujisi´ c et al. [55]r e p o r t e d
signiﬁcantly higher levels of IL-23 in the follicular ﬂuid taken8 Clinical and Developmental Immunology
from follicles containing oocytes, when compared with those
without an oocyte; these authors propose that increased
concentrations of IL-23 in follicles containing oocytes may
indicate a beneﬁcial role for this cytokine in reproduction.
Our observation of lower levels of IL-23 in IUGR samples
seems to support the idea of a beneﬁcial role for IL-23 in
normal pregnancy.
Based on the Th1 shift reported in recurrent miscar-
riage, preterm labor, and pre-eclampsia, our initial premise
was to ascertain whether a similar Th1 bias exists in
IUGR. In a murine model of fetal growth restriction,
induced by Porphyromonas gingivalis infection, Lin et al.
[56] showed this bacterium adversely aﬀects normal fetal
development via direct placental invasion and induction of
fetus-speciﬁc placental immune responses characterized by
a proinﬂammatory Th1-type cytokine proﬁle. They found
t h a tm R N Al e v e l so fI F N γ and IL-2 were signiﬁcantly
increased in placentas of fetuses with growth restriction,
while expression of IL-10 was signiﬁcantly decreased in
the same group. The authors concluded that fetal growth
restriction in this model is associated with a shift in the
placental Th1/Th2 cytokine balance. We do not observe an
obvious Th1/Th2 bias in the cytokine production proﬁles of
maternal PBMC; so we suggest that it is more likely that a
general proinﬂammatory, rather than a more speciﬁc Th1-
bias, operates in IUGR. This contention is based on the lack
of a predominance of Th1/Th2 cytokines such as IFNγ and
IL-4. However, our comparison of cytokine proﬁles in IUGR
with and without placental insuﬃciency showed elevated
production of IL-12 and decreased production in IUGR with
placental insuﬃciency; IL-12 is a Th1-inducing cytokine,
while IL-10 is a Th2-type cytokine and it is tempting to
suggest the possibility of a Th1-bias in IUGR with placental
insuﬃciency when compared to IUGR without placental
insuﬃciency.
5. Conclusions
IUGR is a serious obstetric problem and it is important
that its etiologies and pathogenetic mechanisms be eluci-
dated. Identifying possible associations between IUGR and
immunological eﬀectors such as cytokines will help us
understand the pathophysiology of this disease and deﬁne
markers that can predict this condition. Understanding
immunological mechanisms of normal pregnancy and of
complications such as IUGR could lead to the development
of regimens to improve fetal growth and development.
This study suggests that a proinﬂammatory cytokine bias
exists in maternal peripheral blood mononuclear cells of
women with IUGR when compared to normal pregnancy. It
also supports the notion of a stronger proinﬂammatory tilt
in IUGR with placental insuﬃciency as compared to IUGR
without placental insuﬃciency. This conclusion is based on
levels of cytokines produced by maternal peripheral blood
cells as well as calculated ratios of pro- to anti-inﬂammatory
cytokines. Future research should enable the elucidation of
the roles of cytokines in the pathophysiology of IUGR as
well as the development of new therapies that will aid the
management of this condition.
Appendix
The nine ELISA kits were speciﬁc for the target
human cytokine with no cross-reactivity or interfer-
ence with other cytokines or cytokine receptors.
The IL-4 kit has a sensitivity of 5pg/mL. Coeﬃcient
of variation (CV) for intra-assay precision ranged
between 2.1 and 5.6%, while interassay CVs ranged
from 4.8% to 9.7%.
The IL-6 kit has a sensitivity of 3pg/mL, intra-assay
CVs ranged between 1.6% and 6.8%, while interassay
CVs ranged from 7.9% to 11.6%.
The sensitivity of the IL-8 kit is 8pg/mL; the
intra-assay CVs were between 2.3% and 5.5% and
interassay CVs ranged from 7.6% to 10.1%.
IL-10 was measured at a sensitivity of 5pg/mL,
intra-assay CVs ranged between 3.3% and 4%, while
interassay CVs were between 5.6% and 8.6%.
The IL-12 ELISA kit measures the IL-12 heterodimer,
has an intra-assay CV of 5.5% and interassay CV of
10%.
The sensitivity of the IL-13 ELISA kit is 0.7pg/mL,
intra- and interassay CVs are 6% and 4.6%, respec-
tively.
The human IL-23 Platinum ELISA measures the p19
subunit and has a sensitivity of 4pg/mL, intra-assay
CV is 5.9%, interassay CV is 6.3%.
IFNγ was measured at a sensitivity of 0.08IU/mL,
intra-assay CVs ranged between 2.2% and 12.6% and
interassay CVs ranged from 6.2% to 12.2%.
ThesensitivityoftheTNFαkitis5pg/mL;intra-assay
CVs for this kit were between 1.6% and 10% while
interassay CVs were between 5.4% and 12.8%.
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